Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb;95(2):147-53.
doi: 10.1038/clpt.2013.177. Epub 2013 Sep 23.

A proposal for integrated efficacy-to-effectiveness (E2E) clinical trials

H P Selker  1 , K A Oye  2 , H-G Eichler  3 , N L Stockbridge  4 , C R Mehta  5 , K I Kaitin  6 , N E McElwee  7 , P K Honig  8 , J K Erban  9 , R B D'Agostino  10
Affiliations

A proposal for integrated efficacy-to-effectiveness (E2E) clinical trials

H P Selker et al. Clin Pharmacol Ther. 2014 Feb.

Abstract

We propose an "efficacy-to-effectiveness" (E2E) clinical trial design, in which an effectiveness trial would commence seamlessly upon completion of the efficacy trial. Efficacy trials use inclusion/exclusion criteria to produce relatively homogeneous samples of participants with the target condition, conducted in settings that foster adherence to rigorous clinical protocols. Effectiveness trials use inclusion/exclusion criteria that generate heterogeneous samples that are more similar to the general patient spectrum, conducted in more varied settings, with protocols that approximate typical clinical care. In E2E trials, results from the efficacy trial component would be used to design the effectiveness trial component, to confirm and/or discern associations between clinical characteristics and treatment effects in typical care, and potentially to test new hypotheses. An E2E approach may improve the evidentiary basis for selecting treatments, expand understanding of the effectiveness of treatments in subgroups with particular clinical features, and foster incorporation of effectiveness information into regulatory processes.

PubMed Disclaimer

Comment in

References

    1. Grines C.L., et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N. Engl. J. Med. 1993;328:673–679. - PubMed
    1. Zijlstra F., de Boer M.J., Hoorntje J.C., Reiffers S., Reiber J.H., Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N. Engl. J. Med. 1993;328:680–684. - PubMed
    1. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N. Engl. J. Med. 1997;336:1621–1628. - PubMed
    1. Aversano T., et al. Atlantic Cardiovascular Patient Outcomes Research Team (C-PORT) Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. JAMA. 2002;287:1943–1951. - PubMed
    1. Hassett M.J., O'Malley A.J., Pakes J.R., Newhouse J.P., Earle C.C. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J. Natl. Cancer Inst. 2006;98:1108–1117. - PubMed

Publication types

LinkOut - more resources